Literature DB >> 30347188

Multisite study of the relationships between antemortem [11C]PIB-PET Centiloid values and postmortem measures of Alzheimer's disease neuropathology.

Renaud La Joie1, Nagehan Ayakta2, William W Seeley3, Ewa Borys4, Adam L Boxer3, Charles DeCarli5, Vincent Doré6, Lea T Grinberg3, Eric Huang3, Ji-Hye Hwang3, Milos D Ikonomovic7, Clifford Jack8, William J Jagust9, Lee-Way Jin10, William E Klunk11, Julia Kofler12, Orit H Lesman-Segev3, Samuel N Lockhart13, Val J Lowe14, Colin L Masters15, Chester A Mathis16, Catriona L McLean17, Bruce L Miller3, Daniel Mungas5, James P O'Neil18, John M Olichney5, Joseph E Parisi19, Ronald C Petersen20, Howard J Rosen3, Christopher C Rowe6, Salvatore Spina3, Prashanthi Vemuri8, Victor L Villemagne21, Melissa E Murray22, Gil D Rabinovici2.   

Abstract

INTRODUCTION: We sought to establish the relationships between standard postmortem measures of AD neuropathology and antemortem [11C]PIB-positron emission tomography ([11C]PIB-PET) analyzed with the Centiloid (CL) method, a standardized scale for Aβ-PET quantification.
METHODS: Four centers contributed 179 participants encompassing a broad range of clinical diagnoses, PET data, and autopsy findings.
RESULTS: CL values increased with each CERAD neuritic plaque score increment (median -3 CL for no plaques and 92 CL for frequent plaques) and nonlinearly with Thal Aβ phases (increases were detected starting at phase 2) with overlap between scores/phases. PET-pathology associations were comparable across sites and unchanged when restricting the analyses to the 56 patients who died within 2 years of PET. A threshold of 12.2 CL detected CERAD moderate-to-frequent neuritic plaques (area under the curve = 0.910, sensitivity = 89.2%, specificity = 86.4%), whereas 24.4 CL identified intermediate-to-high AD neuropathological changes (area under the curve = 0.894, sensitivity = 84.1%, specificity = 87.9%). DISCUSSION: Our study demonstrated the robustness of a multisite Centiloid [11C]PIB-PET study and established a range of pathology-based CL thresholds.
Copyright © 2018 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Alzheimer's disease neuropathologic changes; CERAD; Centiloid; Harmonization; Neuropathology; Pittsburgh compound-B; Positron emission tomography; Thal; Threshold; β-amyloid

Mesh:

Substances:

Year:  2018        PMID: 30347188      PMCID: PMC6368897          DOI: 10.1016/j.jalz.2018.09.001

Source DB:  PubMed          Journal:  Alzheimers Dement        ISSN: 1552-5260            Impact factor:   21.566


  44 in total

1.  The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part II. Standardization of the neuropathologic assessment of Alzheimer's disease.

Authors:  S S Mirra; A Heyman; D McKeel; S M Sumi; B J Crain; L M Brownlee; F S Vogel; J P Hughes; G van Belle; L Berg
Journal:  Neurology       Date:  1991-04       Impact factor: 9.910

2.  Early AD pathology in a [C-11]PiB-negative case: a PiB-amyloid imaging, biochemical, and immunohistochemical study.

Authors:  Milos D Ikonomovic; Eric E Abrahamson; Julie C Price; Ronald L Hamilton; Chester A Mathis; William R Paljug; Manik L Debnath; Anne D Cohen; Katsuyoshi Mizukami; Steven T DeKosky; Oscar L Lopez; William E Klunk
Journal:  Acta Neuropathol       Date:  2012-01-24       Impact factor: 17.088

3.  Amyloid vs FDG-PET in the differential diagnosis of AD and FTLD.

Authors:  G D Rabinovici; H J Rosen; A Alkalay; J Kornak; A J Furst; N Agarwal; E C Mormino; J P O'Neil; M Janabi; A Karydas; M E Growdon; J Y Jang; E J Huang; S J Dearmond; J Q Trojanowski; L T Grinberg; M L Gorno-Tempini; W W Seeley; B L Miller; W J Jagust
Journal:  Neurology       Date:  2011-11-30       Impact factor: 9.910

Review 4.  Using Pittsburgh Compound B for in vivo PET imaging of fibrillar amyloid-beta.

Authors:  Ann D Cohen; Gil D Rabinovici; Chester A Mathis; William J Jagust; William E Klunk; Milos D Ikonomovic
Journal:  Adv Pharmacol       Date:  2012

5.  Presenile Alzheimer disease: amyloid plaques in the cerebellum.

Authors:  J D Pro; C H Smith; S M Sumi
Journal:  Neurology       Date:  1980-08       Impact factor: 9.910

6.  Cerebral PET with florbetapir compared with neuropathology at autopsy for detection of neuritic amyloid-β plaques: a prospective cohort study.

Authors:  Christopher M Clark; Michael J Pontecorvo; Thomas G Beach; Barry J Bedell; R Edward Coleman; P Murali Doraiswamy; Adam S Fleisher; Eric M Reiman; Marwan N Sabbagh; Carl H Sadowsky; Julie A Schneider; Anupa Arora; Alan P Carpenter; Matthew L Flitter; Abhinay D Joshi; Michael J Krautkramer; Ming Lu; Mark A Mintun; Daniel M Skovronsky
Journal:  Lancet Neurol       Date:  2012-06-28       Impact factor: 44.182

7.  Magnetic resonance imaging signatures of tissue pathology in frontotemporal dementia.

Authors:  Jennifer L Whitwell; Keith A Josephs; Martin N Rossor; John M Stevens; Tamas Revesz; Janice L Holton; Safa Al-Sarraj; Alison K Godbolt; Nick C Fox; Jason D Warren
Journal:  Arch Neurol       Date:  2005-09

8.  Post-mortem correlates of in vivo PiB-PET amyloid imaging in a typical case of Alzheimer's disease.

Authors:  Milos D Ikonomovic; William E Klunk; Eric E Abrahamson; Chester A Mathis; Julie C Price; Nicholas D Tsopelas; Brian J Lopresti; Scott Ziolko; Wenzhu Bi; William R Paljug; Manik L Debnath; Caroline E Hope; Barbara A Isanski; Ronald L Hamilton; Steven T DeKosky
Journal:  Brain       Date:  2008-03-12       Impact factor: 13.501

9.  In vivo staging of regional amyloid deposition.

Authors:  Michel J Grothe; Henryk Barthel; Jorge Sepulcre; Martin Dyrba; Osama Sabri; Stefan J Teipel
Journal:  Neurology       Date:  2017-10-18       Impact factor: 11.800

10.  Performance of [18F]flutemetamol amyloid imaging against the neuritic plaque component of CERAD and the current (2012) NIA-AA recommendations for the neuropathologic diagnosis of Alzheimer's disease.

Authors:  Stephen Salloway; Jose E Gamez; Upinder Singh; Carl H Sadowsky; Teresa Villena; Marwan N Sabbagh; Thomas G Beach; Ranjan Duara; Adam S Fleisher; Kirk A Frey; Zuzana Walker; Arvinder Hunjan; Yavir M Escovar; Marc E Agronin; Joel Ross; Andrea Bozoki; Mary Akinola; Jiong Shi; Rik Vandenberghe; Milos D Ikonomovic; Paul F Sherwin; Gill Farrar; Adrian P L Smith; Christopher J Buckley; Dietmar Rudolf Thal; Michelle Zanette; Craig Curtis
Journal:  Alzheimers Dement (Amst)       Date:  2017-07-01
View more
  61 in total

1.  Sensitivity-Specificity of Tau and Amyloid β Positron Emission Tomography in Frontotemporal Lobar Degeneration.

Authors:  Alma Ghirelli; Nirubol Tosakulwong; Stephen D Weigand; Heather M Clark; Farwa Ali; Hugo Botha; Joseph R Duffy; Rene L Utianski; Marina Buciuc; Melissa E Murray; Sydney A Labuzan; Anthony J Spychalla; Nha Trang Thu Pham; Christopher G Schwarz; Matthew L Senjem; Mary M Machulda; Matthew Baker; Rosa Rademakers; Massimo Filippi; Clifford R Jack; Val J Lowe; Joseph E Parisi; Dennis W Dickson; Keith A Josephs; Jennifer L Whitwell
Journal:  Ann Neurol       Date:  2020-09-12       Impact factor: 10.422

2.  Regional Tau Effects on Prospective Cognitive Change in Cognitively Normal Older Adults.

Authors:  Xi Chen; Kaitlin E Cassady; Jenna N Adams; Theresa M Harrison; Suzanne L Baker; William J Jagust
Journal:  J Neurosci       Date:  2020-11-20       Impact factor: 6.167

3.  Temporal variant of frontotemporal dementia in C9orf72 repeat expansion carriers: two case studies.

Authors:  Francesca Caso; Federica Agosta; Giuseppe Magnani; Rosalinda Cardamone; Valentina Borghesani; Zachary Miller; Nilo Riva; Renaud La Joie; Giovanni Coppola; Lea T Grinberg; William W Seeley; Bruce L Miller; Maria Luisa Gorno-Tempini; Massimo Filippi
Journal:  Brain Imaging Behav       Date:  2020-04       Impact factor: 3.978

4.  The clinical feasibility of deep learning-based classification of amyloid PET images in visually equivocal cases.

Authors:  Hye Joo Son; Jungsu S Oh; Minyoung Oh; Soo Jong Kim; Jae-Hong Lee; Jee Hoon Roh; Jae Seung Kim
Journal:  Eur J Nucl Med Mol Imaging       Date:  2019-12-06       Impact factor: 9.236

5.  Association Between Ambient Air Pollution and Amyloid Positron Emission Tomography Positivity in Older Adults With Cognitive Impairment.

Authors:  Leonardo Iaccarino; Renaud La Joie; Orit H Lesman-Segev; Eunice Lee; Lucy Hanna; Isabel E Allen; Bruce E Hillner; Barry A Siegel; Rachel A Whitmer; Maria C Carrillo; Constantine Gatsonis; Gil D Rabinovici
Journal:  JAMA Neurol       Date:  2021-02-01       Impact factor: 18.302

6.  Defining the Lowest Threshold for Amyloid-PET to Predict Future Cognitive Decline and Amyloid Accumulation.

Authors:  Michelle E Farrell; Shu Jiang; Aaron P Schultz; Michael J Properzi; Julie C Price; J Alex Becker; Heidi I L Jacobs; Bernard J Hanseeuw; Dorene M Rentz; Victor L Villemagne; Kathryn V Papp; Elizabeth C Mormino; Rebecca A Betensky; Keith A Johnson; Reisa A Sperling; Rachel F Buckley
Journal:  Neurology       Date:  2020-11-16       Impact factor: 9.910

7.  Diagnostic Accuracy of Amyloid versus 18 F-Fluorodeoxyglucose Positron Emission Tomography in Autopsy-Confirmed Dementia.

Authors:  Orit H Lesman-Segev; Renaud La Joie; Leonardo Iaccarino; Iryna Lobach; Howard J Rosen; Sang Won Seo; Mustafa Janabi; Suzanne L Baker; Lauren Edwards; Julie Pham; John Olichney; Adam Boxer; Eric Huang; Marilu Gorno-Tempini; Charles DeCarli; Mackenzie Hepker; Ji-Hye L Hwang; Bruce L Miller; Salvatore Spina; Lea T Grinberg; William W Seeley; William J Jagust; Gil D Rabinovici
Journal:  Ann Neurol       Date:  2020-12-07       Impact factor: 10.422

8.  Longitudinal anatomic, functional, and molecular characterization of Pick disease phenotypes.

Authors:  Jennifer L Whitwell; Nirubol Tosakulwong; Christopher C Schwarz; Matthew L Senjem; Anthony J Spychalla; Joseph R Duffy; Jon Graff-Radford; Mary M Machulda; Bradley F Boeve; David S Knopman; Ronald C Petersen; Val J Lowe; Clifford R Jack; Dennis W Dickson; Joseph E Parisi; Keith A Josephs
Journal:  Neurology       Date:  2020-09-28       Impact factor: 9.910

9.  Principal-Component Analysis-Based Measures of PET Data Closely Reflect Neuropathologic Staging Schemes.

Authors:  Ganna Blazhenets; Lars Frings; Arnd Sörensen; Philipp T Meyer
Journal:  J Nucl Med       Date:  2020-10-23       Impact factor: 10.057

10.  Crossed cerebellar diaschisis on 18F-FDG PET: Frequency across neurodegenerative syndromes and association with 11C-PIB and 18F-Flortaucipir.

Authors:  Karine Provost; Renaud La Joie; Amelia Strom; Leonardo Iaccarino; Lauren Edwards; Taylor J Mellinger; Julie Pham; Suzanne L Baker; Bruce L Miller; William J Jagust; Gil D Rabinovici
Journal:  J Cereb Blood Flow Metab       Date:  2021-03-10       Impact factor: 6.200

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.